Literature DB >> 12087527

Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System.

Douglas Shaffer1, Sarah Singer, Joyce Korvick, Peter Honig.   

Abstract

In this case series, we examined concomitant risk factors mentioned in reports of torsades de pointes, a rare ventricular arrhythmia, that occurred in association with administration of macrolide antimicrobials (e.g., azithromycin, clarithromycin, dirithromycin, and erythromycin). Increasing age, female sex, and concomitant diseases and drug administration believed to increase risks for torsades de pointes were commonly reported.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12087527     DOI: 10.1086/340861

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  36 in total

1.  Adverse drug event monitoring at the Food and Drug Administration.

Authors:  Syed Rizwanuddin Ahmad
Journal:  J Gen Intern Med       Date:  2003-01       Impact factor: 5.128

2.  Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System.

Authors:  Elisabetta Poluzzi; Emanuel Raschi; Domenico Motola; Ugo Moretti; Fabrizio De Ponti
Journal:  Drug Saf       Date:  2010-04-01       Impact factor: 5.606

3.  Azithromycin and the risk of cardiovascular death.

Authors:  Wayne A Ray; Katherine T Murray; Kathi Hall; Patrick G Arbogast; C Michael Stein
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

Review 4.  Targeted Cancer Therapies and QT Interval Prolongation: Unveiling the Mechanisms Underlying Arrhythmic Complications and the Need for Risk Stratification Strategies.

Authors:  Rezarta Cuni; Iris Parrini; Riccardo Asteggiano; Maria Rosa Conte
Journal:  Clin Drug Investig       Date:  2017-02       Impact factor: 2.859

Review 5.  Impact of Age and Sex on QT Prolongation in Patients Receiving Psychotropics.

Authors:  Simon W Rabkin
Journal:  Can J Psychiatry       Date:  2015-05       Impact factor: 4.356

Review 6.  [Treatment of postoperative impairment of gastrointestinal motility, cholangitis and pancreatitis].

Authors:  T Schulze; C-D Heidecke
Journal:  Chirurg       Date:  2015-06       Impact factor: 0.955

7.  Use of azithromycin and risk of ventricular arrhythmia.

Authors:  Gianluca Trifirò; Maria de Ridder; Janet Sultana; Alessandro Oteri; Peter Rijnbeek; Serena Pecchioli; Giampiero Mazzaglia; Irene Bezemer; Edeltraut Garbe; Tania Schink; Elisabetta Poluzzi; Trine Frøslev; Mariam Molokhia; Igor Diemberger; Miriam C J M Sturkenboom
Journal:  CMAJ       Date:  2017-04-18       Impact factor: 8.262

8.  A novel genetic modifier for clarithromycin-related cardiac arrhythmia risk?

Authors:  Jules C Hancox; Chunyun Du; Aziza El Harchi; Adrian Baranchuk; Henggui Zhang
Journal:  Ther Adv Infect Dis       Date:  2014-04

9.  Effect of macrolide and fluoroquinolone antibacterials on the risk of ventricular arrhythmia and cardiac arrest: an observational study in Italy using case-control, case-crossover and case-time-control designs.

Authors:  Antonella Zambon; Hernan Polo Friz; Paolo Contiero; Giovanni Corrao
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 10.  Cardiac risks associated with antibiotics: azithromycin and levofloxacin.

Authors:  Zhiqiang Kevin Lu; Jing Yuan; Minghui Li; S Scott Sutton; Gowtham A Rao; Sony Jacob; Charles L Bennett
Journal:  Expert Opin Drug Saf       Date:  2014-12-10       Impact factor: 4.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.